Clascoterone
Brand names: Winlevi
Clascoterone is a topical androgen receptor inhibitor applied to the skin for the treatment of acne vulgaris.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It competes with androgens such as dihydrotestosterone for binding to androgen receptors in the sebaceous gland and hair follicle, reducing sebum production and the inflammation that contribute to acne.
Prescribing in practice
- Local skin reactions and signs suggestive of hypothalamic-pituitary-adrenal axis suppression have been reported, particularly with extensive or prolonged use, so apply only to affected areas as directed.
- It is for topical use only and should not be applied to the eyes, mouth or other mucous membranes.
- Apply to clean, dry skin and avoid use on cut, broken or eczematous skin.
Monitoring
Monitor clinically for treatment response and local irritation; consider HPA-axis effects if used over large areas for prolonged periods.
Counselling the patient
- Apply a thin layer to the affected areas of the face as directed.
- Some local dryness, redness or scaling can occur.
- Use only on the skin and keep it away from the eyes and mouth.
Evidence & guidelines
Clascoterone is a topical anti-androgen licensed for the treatment of acne vulgaris on the basis of its clinical trial programme.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD